FDA approves Ventana PD-L1 (SP263) assay for non-small cell lung cancer detection.- Roche
Phase III ECZTRA 6 trial of Adtralza meets its primary endpoints at 16 weeks for atopic dermatitis.- LEO Pharma
Phase III SOLSTICE trial of Lonsurf fails to meet primary endpoint in colorectal cancer.- Servier
EU approves Keytruda plus chemo for metastatic triple-negative breast cancer.- Merck Inc
Two phase III studies of Xiaflex show efficacy in Peyronie's disease.- Endo International
Baxter and bioMérieux announce CE Mark for NEPHROCLEAR CCL14 test to predict persistent severe acute kidney injury.
Positive pivotal Phase III PRIME2 trial reports on Dupixent in adults with uncontrolled prurigo nodularis
Phase III trial of Comirnaty shows efficacy as booster for COVID-19.
FDA approves Dupixent as add-on treatment for moderate-to-severe asthma.
EU approves Opdivo and chemo for HER2-negative gastric, gastroesophageal junction or oesophageal adenocarcinoma.
Ferriprox approved in Canada for treatment of iron overload in patients with sickle cell disease.
Phase III EMERALD study of RAD 1901 meets primary endpoints in ER+/HER2- breast cancer.
FDA approves expanded indication of Biktarvy for treatment of HIV-1 in pediatric populations.
Sorrento announces that Covistix (COVID-19 virus rapid antigen detection test has received a CE Mark and registration of the device.
bluebird bio Inc., to spin off its oncology programs to 2seventy bio
Zai Lab + Entasis Therapeutics announce positive topline results for sulbactam-durlobactam (SUL-DUR)
Valneva reports positive phase III results for inactivated, adjuvanted COVID-19 vaccine candidate VLA 2001.
Atea Pharmaceuticals provides update and topline results for phase II MOONSONG trial.
Oyster Point Pharma announces FDA approval of Tyrvaya nasal spray for the treatment of the signs and symptoms of dry eye disease.
Novavax statement on initial Com-COV2 phase II clinical trial results presented at World Vaccine Congress Europe
Sage Therapeutics + Biogen plan to submit an NDA for zuranolone.
FDA approval for sBLA for Dextenza for intracanalicular use for treatment of ocular itching associated with conjunctivitis.
Adamis receives FDA approval for Zimhi a new high-dose naloxone product for the treatment of opioid overdose.
Phase III ATOM trial of Tymlos shows positive results in osteoporosis.
Phase III PHALCON-EE trial of Takecab meets its primary and key secondary endpoints in erosive oesophagitis.
FDA provides a complete response letter for OMS 721 in hematopoietic stem cell transplant.
Phase III ORIENT-31 trial of Tyvyt + Byvasda meets primary endpoint in non-small cell lung cancer.
Biosimilars: an option to alleviate the heavy burden of immune-mediated inflammatory diseases
Clinical value beyond price alone: anti-TNF biosimilars enable early treatment
Clinical value beyond price alone: biosimilars improve patient access to treatment
Long-term topical management of psoriasis: the road ahead
Over the horizon: early stage trials for NASH
Phase II trials and stem cell therapies
The next global epidemic
The latest treatments in NASH
The future of organ transplantation
Complications of stem cell transplants
Treating rejection in organ transplants
Challenges in transplant organ rejection
Biologic efficacy for complications associated with moderate-to-severe psoriasis
Moderate-to-severe psoriasis: treatment for young women
Migraine treatments: On the horizon
An independent review of current treatments for migraine
Migraine: The forgotten epidemic?
NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com
Senolytics: Can we treat age-related diseases with a single drug
Long-term disease control in Psoriasis: announcing a new project
Senolytics: an emerging therapeutic for the prevention and treatment of cardiovascular disease
Targeted therapies in triple negative breast cancer
Targeted therapies in HER2 negative breast cancer
Targeted therapies in HER2 positive breast cancer
Breast Cancer- Targeted therapies
World Congress of Dermatology 2019 - A new ERA for global Dermatology
Opioids - Over the horizon
Opioids: The war on drugs
Opioids: the future and challenging the epidemic
Moderate-to-severe psoriasis: the disease burden and unmet needs in different patient groups
Replacement therapies for opioid drugs in pain treatment
Microbiomes: is there nothing that they can't do?
Shaken not stirred your bacteriophage cocktail
From Acne to Immunotherapy: new applications for FMT (Faecal Microbiota Transplantation)
Part Four | Obesity, Type 2 diabetes and cardiovascular disease: Finding the magic bullet
Part Three | Next generation obesity therapies
Part two | New hopes for treatment in the global obesity epidemic
Part One | The effects of obesity and the links to diabetes and cardiovascular disease: now and in the future
Key findings from the SWIPE study
COPD experts tackle key topics in our latest Q&A
Your guide to IBD novel treatments and assessment tools
Immobility and sleep disruption in the ICU - Latest recommendations
UPDATE: Urticaria e-learning new modules & symposia highlights
Unravelling the microbiome - health through happy communities
Psoriasis Knowledge Centre relaunches on Medthority.com
Atopic Dermatitis Knowledge Centre launched on Medthority.com
Reformulation of postnatal haemorrhage prophylaxis could save thousands in lower income countries
Medical cannabis - a novel approach to pain control
Accredited CME: The future of urticaria - advances in CSU research - launched to Medthority.com
New inflammatory bowel disease (IBD) Knowledge Centre
New rare disease platform launched for Hunter Syndrome
New publication digest and infographic for Cardiologists.
Genetic variation and drug efficacy - could this pave the way for personalised medicines?
Neue Informationsmaterialien in deutscher Sprache zum Management von Schmerzen, Agitation und Delir auf der Intensivstation (in Zusammenarbeit mit Orion Pharma)
New: Symposium videos & presentations for immunologists, dermatologists and allergists
Magnetic nanoparticles could help rejuvenate damaged hearts
New findings may pave the way for novel HIV drugs
Adoptive T cell therapy, advanced melanoma and survival
Appetite and the brain - white matter integrity to blame?
Vitamin D in pregnancy - is it any good?
How close are we to a disease-modifying treatment for Alzheimer’s?
Japan's aging population and Alzheimer's
Focus on Primary Care - helping GPs diagnose, manage and treat urticaria
Prof Vincent interview - Defining the eCASH Concept in PAD Management
Inactivity in the elderly increases their cardiovascular risk by 14%
Close social relationships may slow cognitive decline
Type 2 diabetes risk may be increased by statin use in susceptible individuals
Improving non-alcoholic steatohepatitis care – is the finishing line in sight?
Acute myeloid leukaemia: Hope for new treatments
Left ventricular assist devices – A viable therapeutic option for heart failure?
Antibody-drug conjugates (ADCs)
Cancer immunotherapies
Horizons: a series of opinion & insight articles on disruptive healthcare in practice
The way ahead for cystic fibrosis
Schizophrenia: challenges in a crowded market
Nonalcoholic steatohepatitis: the next global epidemic?
Launch of LAL-Deficiency Knowledge Centre
Latest updates to the Chronic Spontaneous Urticaria Knowledge Centre
Launch of Oral Anticoagulation Reversal Knowledge Centre
SGLT2 Inhibitors: good news for diabetes
Will Glucagon-like peptide-1 agonists dominate the Type 2 Diabetes market?
Launch of Chronic Spontaneous Urticaria CME activity
Launch of new Cystic Fibrosis Knowledge Centre
Launch of new Chronic Lymphocytic Leukaemia CME
Launch of updated Hypogonadism Knowledge Centre
New approaches to anticoagulant therapy
ESOT 2015 speaker slides added to AIKN-IFI
New type 2 diabetes CME activity now available on Medthority.com
ATS 2015 symposium materials added to COPD Knowledge Centre
WCD 2015 videos added to the Chronic Spontaneous Urticaria (CSU) Knowledge Centre
Case studies added to Chronic Spontaneous Urticaria (CSU) Knowledge Centre
New hyperammonaemia resource developed for Medthority.com users
Chronic myelogenous leukaemia: a remarkable success story
Bedwetting resource receives a mobile-friendly transformation
IL-17A treatment section added to Psoriasis Knowledge Centre
Free haemato-oncology report added to AIKN-IFI congresses section
Parkinson's disease: the struggle to control symptoms
Metastatic melanoma: the new immunotherapies
Exciting developments and new approaches in psoriasis
